论文部分内容阅读
〔目的〕探讨增强剂量CHOP方案治疗非霍奇金淋巴瘤的临床完全缓解率和3年生存率及骨髓抑制等情况。（方法）对51例非霍奇金淋巴瘤患者进行增强剂量CHOP方案治疗及良好的支持治疗并长期、定期治疗及随访。（结果）全组完全缓解率为784％；3年生存率为779％。（结论）增强剂量CHOP方案与传统CHOP方案相比在完全缓解率和3年生存率上有明显提高，而其骨髓抑制等毒副反应未见明显增加。
[Objective] To investigate the clinical complete remission rate, 3-year survival rate, and myelosuppression of non-Hodgkin’s lymphoma treated with the enhanced dose CHOP regimen. (Methods) 51 patients with non-Hodgkin’s lymphoma were treated with enhanced dose CHOP regimen and good supportive therapy, and long-term, regular treatment and follow-up. (Results) The complete remission rate in the whole group was 784%; the 3-year survival rate was 779%. (Conclusion) Compared with the traditional CHOP regimen, the CHOP regimen with the enhanced dose has a significant increase in the complete remission rate and 3-year survival rate, but no significant increase in toxic side effects such as myelosuppression.